Skip to main content

2022 Startup Exit Awards: Wugen's $172M funding round helps develop new cancer treatments

Since raising $172 million from investors, drug development startup Wugen has made significant progress on its efforts to develop new cancer treatments, including the launch of a clinical trial.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.